Back to top

Image: Bigstock

Top Ranked Growth Stocks to Buy for January 14th

Read MoreHide Full Article

Here are four stocks with buy ranks and strong growth characteristics for investors to consider today, January 14th:

Cimpress plc (CMPR - Free Report) : This mass customization services provider, which carries a Zacks Rank #1 (Strong Buy), has witnessed the Zacks Consensus Estimate for its current year earnings increasing 6.8% over the last 60 days.

Cimpress has a PEG ratio of 1.17 compared with 2.16 for the industry. The company possesses a Growth Score of A.

Cimpress N.V PEG Ratio (TTM)

Cimpress N.V PEG Ratio (TTM)

Cimpress N.V peg-ratio-ttm | Cimpress N.V Quote

Focus Financial Partners Inc. (FOCS - Free Report) : This wealth management services provider, which carries a Zacks Rank #1, has witnessed the Zacks Consensus Estimate for its current year earnings increasing 0.7% over the last 60 days.

Focus Financial Partners has a PEG ratio of 0.49, compared with 1.28 for the industry. The company possesses a Growth Score of A.

Berry Global Group, Inc. (BERY - Free Report) : This packaging solutions provider, which carries a Zacks Rank #1, has witnessed the Zacks Consensus Estimate for its current year earnings increasing 6.8% over the last 60 days.

Berry Global has a PEG ratio of 0.88, compared with 1.87 for the industry. The company possesses a Growth Score of B.

Arcosa, Inc. (ACA - Free Report) : This manufacturer and marketer of infrastructure-related products and services, which carries a Zacks Rank #1, has witnessed the Zacks Consensus Estimate for its current year earnings increasing 2.4% over the last 60 days.

Arcosa has a PEG ratio of 1.40, compared with 1.43 for the industry. The company possesses a Growth Score of B.

Arcosa, Inc. PEG Ratio (TTM)

Arcosa, Inc. PEG Ratio (TTM)

Arcosa, Inc. peg-ratio-ttm | Arcosa, Inc. Quote

See the full list of top ranked stocks here.

Learn more about the Growth score and how it is calculated here.

Breakout Biotech Stocks with Triple-Digit Profit Potential

The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.

Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.

See these 7 breakthrough stocks now>>